Kiho Tanaka

Ms. Kiho Tanaka

Department of Infectious Diseases, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
PCPaula Maria Cevaal
Paula Maria Cevaal
SKStanislav Kan
Stanislav Kan
BFBridget M. Fisher
Bridget M. Fisher
MMMichael A. Moso
Michael A. Moso
ATAbigail Tan
Abigail Tan
MRMichael Roche
Michael Roche
A major hurdle to curing HIV is the persistence of integrated proviruses in resting CD4+ T cells that remain in a transcriptionally silent, latent state. One strategy to eradicate latent HIV is to activate viral transcription, followed by elimination of infected cells through virus-mediated cytotoxicity or immune-mediated clearance. We hypothesised that mRNA-lipid nanoparticle (LNP) technology would provide an opportunity to deliver mRNA encoding proteins able to reverse HIV latency in resting CD4+ T cells. Here we develop an LNP formulation (LNP X) with unprecedented potency to deliver mRNA to hard-to-transfect resting CD4+ T cells in the absence of cellular toxicity or activation. Encapsulating an mRNA encoding the HIV Tat protein, an activator of HIV transcription, LNP X enhances HIV transcription in ex vivo CD4+ T cells from people living with HIV. LNP X further enables the delivery of clustered regularly interspaced short palindromic repeats (CRISPR) activation machinery to modulate both viral and host gene transcription. These findings offer potential for the development of a range of nucleic acid-based T cell therapeutics.

21 May 2022 in Viruses
Verified
Journal Article
Open access
PDF file
KTKiho Tanaka
Kiho Tanaka
PCPaula Maria Cevaal
Paula Maria Cevaal
RPRachel Pascoe
Rachel Pascoe
Three early-career female virologists sat down with a distinguished Nobel laureate to discuss two pandemics, 39 years apart